Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2019

View Archived Issues

Outside of cell, intracellular enzyme is HER2 inhibitor

Relaxation Rx for hypertrophic cardiomyopathy

Neurogenic pain receptor identified

Bacterial virulence factor contributes to brain damage in AD

New sphingosine 1-phosphate receptor antagonists reported by Galapagos

Sanofi patents new antimalarials

Inflazome describes NLRP3 inflammasome inhibitors

Peking University discovers STAT3 inhibitors

Selection Bioscience patents indoleamine 2,3-dioxygenase 1 inhibitors

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine describe RORC agonists/inverse agonists

FDA approves I-Mab's IND to initiate phase I/Ib study of TJC-4

First volunteer dosed in phase I study of HBV therapy DCR-HBVS

LJ-2618, a new selenonucleoside, inhibits prostate cancer tumor growth in vivo

GB-1211 begins first-in-human trial in healthy volunteers and subjects with NASH and liver fibrosis

Enyo Pharma initiates phase IIa study of EYP-001a in NASH

Horizon Discovery partners with Rutgers University on base editing platform

MedImmune studies MEDI-7247 in phase I/Ib trial for advanced or metastatic solid tumors

Rocket studies RP-L201 in pediatric patients with severe leukocyte adhesion deficiency-I

Phase I data presented for mAb114 monoclonal antibody for treating Ebola virus

Small molecule targets the most common genetic cause of ALS

Topline results from second phase III study of tanezumab in OA pain

Triphase enters strategic collaboration with Celgene for TRPH-395

Chinese IND clearance for CARsgen's GPC3-CAR-T cells for solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...